Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Consensus Rating of “Hold” by Brokerages

Gyre Therapeutics, Inc. (NASDAQ:GYRE) has been assigned an average rating of “Hold” from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $17.00.

GYRE has been the topic of several research analyst reports. Wall Street Zen raised shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Finally, Jefferies Financial Group began coverage on Gyre Therapeutics in a report on Friday, October 10th. They set a “buy” rating and a $16.00 target price on the stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after acquiring an additional 1,996 shares during the period. SBI Securities Co. Ltd. boosted its position in shares of Gyre Therapeutics by 87.9% during the 2nd quarter. SBI Securities Co. Ltd. now owns 232,299 shares of the company’s stock valued at $1,707,000 after purchasing an additional 108,670 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Gyre Therapeutics by 28.6% during the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after purchasing an additional 89,390 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after purchasing an additional 3,244 shares in the last quarter. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Stock Down 0.7%

Shares of NASDAQ GYRE opened at $8.03 on Thursday. Gyre Therapeutics has a fifty-two week low of $6.11 and a fifty-two week high of $13.75. The firm’s 50-day simple moving average is $7.62 and its 200 day simple moving average is $7.65. The stock has a market cap of $773.53 million, a P/E ratio of 267.76 and a beta of 1.99.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.